Literature DB >> 10659019

Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth.

I E McCutcheon1, K E Friend, T M Gerdes, B M Zhang, D M Wildrick, G N Fuller.   

Abstract

OBJECT: Although human meningioma cells have been heterotopically implanted in nude mice, introducing these cells into intracranial locations seems more likely to reproduce normal patterns of tumor growth. To provide an orthotopic xenograft model of meningioma, the authors implanted a controlled quantity of meningioma cells at subdural and intracerebral sites in athymic mice.
METHODS: Malignant (one tumor), atypical (two tumors), or benign (three tumors) meningiomas were placed into primary cell cultures. Cells (10(6)/10 microl) from these cultures and from an immortalized malignant meningioma cell line, IOMM-Lee, were injected with stereotactic guidance into the frontal white matter or subdural space of athymic mice. Survival curves were plotted for mice receiving tumor cells of each histological type and according to injection site. Other mice were killed at intervals and their heads were sectioned whole. Hematoxylin and eosin staining of these sections revealed the extent of tumor growth.
CONCLUSIONS: The median length of survival for mice with malignant, atypical, or benign tumors was 19, 42, or longer than 84 days, respectively. Atypical and malignant tumors were invasive, but did not metastasize extracranially. Malignant tumors uniformly showed leptomeningeal dissemination and those implanted intracerebrally grew locally and spread noncontiguously to the ventricles, choroid plexus, convexities, and skull base. Tumors formed in only 50% of mice injected with benign meningioma cells, whereas injection of more aggressive cells was uniformly successful at tumor production. The three types of human meningiomas grown intracranially in athymic mice maintained their relative positions in the spectrum of malignancy. However, atypical meningiomas became more aggressive after xenografting and acquired malignant features, implying that there had been immune constraint in the original host. Tumor cells injected into brain parenchyma migrated to more optimal environments and grew best there. This model provides insights into the biology of meningiomas and may be useful for testing new therapies.

Entities:  

Mesh:

Year:  2000        PMID: 10659019     DOI: 10.3171/jns.2000.92.2.0306

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  20 in total

1.  Chk2-mediated G2/M cell cycle arrest maintains radiation resistance in malignant meningioma cells.

Authors:  Venkateswara Rao Gogineni; Arun Kumar Nalla; Reshu Gupta; Dzung H Dinh; Jeffrey D Klopfenstein; Jasti S Rao
Journal:  Cancer Lett       Date:  2011-09-06       Impact factor: 8.679

2.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

Review 3.  Meningioma mouse models.

Authors:  Michel Kalamarides; Matthieu Peyre; Marco Giovannini
Journal:  J Neurooncol       Date:  2010-08-24       Impact factor: 4.130

4.  Restoring soluble guanylyl cyclase expression and function blocks the aggressive course of glioma.

Authors:  Haifeng Zhu; Jessica Tao Li; Fang Zheng; Emil Martin; Alexander Y Kots; Joshua S Krumenacker; Byung-Kwon Choi; Ian E McCutcheon; Norman Weisbrodt; Oliver Bögler; Ferid Murad; Ka Bian
Journal:  Mol Pharmacol       Date:  2011-09-09       Impact factor: 4.436

5.  A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus.

Authors:  Fares Nigim; Shin-Ichi Esaki; Michael Hood; Nina Lelic; Marianne F James; Vijaya Ramesh; Anat Stemmer-Rachamimov; Daniel P Cahill; Priscilla K Brastianos; Samuel D Rabkin; Robert L Martuza; Hiroaki Wakimoto
Journal:  Neuro Oncol       Date:  2016-03-06       Impact factor: 12.300

6.  Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Authors:  Sarah S Burns; Elena M Akhmametyeva; Janet L Oblinger; Matthew L Bush; Jie Huang; Volker Senner; Ching-Shih Chen; Abraham Jacob; D Bradley Welling; Long-Sheng Chang
Journal:  Cancer Res       Date:  2012-11-14       Impact factor: 12.701

7.  Radiation-induced hypomethylation triggers urokinase plasminogen activator transcription in meningioma cells.

Authors:  Kiran Kumar Velpula; Venkateswara Rao Gogineni; Arun Kumar Nalla; Dzung H Dinh; Jasti S Rao
Journal:  Neoplasia       Date:  2013-02       Impact factor: 5.715

8.  MiRNA-mediated tumor specific delivery of TRAIL reduced glioma growth.

Authors:  Yongli Bo; Guocai Guo; Weicheng Yao
Journal:  J Neurooncol       Date:  2013-01-22       Impact factor: 4.130

9.  N-ethyl-N-nitrosourea (ENU)-induced meningiomatosis and meningioma in p16(INK4a)/p19(ARF) tumor suppressor gene-deficient mice.

Authors:  James P Morrison; Hiroshi Satoh; Julie Foley; John L Horton; June K Dunnick; Grace E Kissling; David E Malarkey
Journal:  Toxicol Pathol       Date:  2007-10       Impact factor: 1.902

10.  Bioluminescent imaging of intracranial vestibular schwannoma xenografts in NOD/SCID mice.

Authors:  Brian A Neff; Stephen G Voss; Cory Allen; Mark A Schroeder; Colin L W Driscoll; Michael J Link; Evanthia Galanis; Jann N Sarkaria
Journal:  Otol Neurotol       Date:  2009-01       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.